Ligand Pharmaceuticals (LGND) Interest & Investment Income (2010 - 2026)

Ligand Pharmaceuticals has disclosed Interest & Investment Income across 13 years of filings, most recently posting $6.7 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $6.7 million, up 275.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.5 million (up 137.55% YoY), and the FY2025 annual result was $13.7 million, up 69.57% from the prior year.
• Interest & Investment Income came in at $6.7 million for Q1 2026 at Ligand Pharmaceuticals, up from $6.4 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $6.7 million in Q1 2026 to a low of $134000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $1.8 million (2025), against an average of $2.2 million.
• Across the five-year window, Interest & Investment Income plunged 54.73% in 2022 and soared 970.9% in 2023, its largest moves.
• Ligand Pharmaceuticals' Interest & Investment Income stood at $1.0 million in 2022, then surged by 65.49% to $1.7 million in 2023, then gained by 14.06% to $1.9 million in 2024, then soared by 231.07% to $6.4 million in 2025, then advanced by 4.1% to $6.7 million in 2026.
• The last three Interest & Investment Income figures came in at $6.7 million (Q1 2026), $6.4 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.